Stefan Sack
Research Subjects
Stefan Sack has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Raimund Erbel
From the Department of Cardiology (S.S., P.K., R.E.), West German Heart Center, Essen, Germany; the Department of Medicine (L.B.), Montreal Heart Institute, Montréal, Canada; the Department of Cardiology (L.P., V.L., P.L.), University Hospital of Liège, Liège, Belgium; the Department of Cardiology (R.H., P.S.), R-WTH University Hospital Aachen, Aachen, Germany; the Cardiovascular Center OLV Ziekenhuis (J.B., M.V.), Aalst, Belgium; Medical College of Wisconsin (D.M.), Milwaukee, Wis; and...
3 shared publications- Florian Eyer
Department of Clinical Toxicology and Poison Center Munich, Department of Internal Medicine II, TUM School of Medicine and Health, Technical University of Munich, TUM University Hospital Munich, Munich, Germany
2 shared publications - Stefanie Geith
Department of Clinical Toxicology and Poison Center Munich, Department of Internal Medicine II, TUM School of Medicine and Health, Technical University of Munich, TUM University Hospital Munich, Munich, Germany
2 shared publications - Adinda Harle
Department of Infectious Diseases and Tropical Medicine (DITM), University Hospital, Ludwig-Maximilians-University, Leopoldstrasse 5, 80802, Munich, Germany
1 shared publication - Amos Katz
Department of Cardiology, Barzilai Medical Center, Ben-Gurion University of the Negev, Ashkelon, Israel
1 shared publication - Cathrine Haller
Department of Cardiology, Pneumology, and Intensive Care Medicine, Klinikum Schwabing, Akademisches Lehrkrankenhaus der Ludwig-Maximilians-Universität, Kölner Platz 1, 80804, Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 12 July 2018
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 12 (1) , 201
Lethal outcome of granulomatous acanthamoebic encephalitis in a man who was human immunodeficiency virus-positive: a case report
Acanthamoeba species can cause disseminating infections in immunocompromised individuals. Here, we report a case of granulomatous acanthamoebic encephalitis with a lethal outcome in a 54-year-old German man who was human immunodeficiency virus-positive. The diagnosis was based on symptoms of progressive neurological deficits, including sensorimotor paralysis of his right leg and deteriorating alertness. Due to the rapid course and rather late diagnosis of the infection, effective treatment could not be applied and he died 12 days after hospital admission. To the best of our knowledge, this is the second case of granulomatous acanthamoebic encephalitis reported within Germany. Our case highlights the importance of early diagnosis of granulomatous acanthamoebic encephalitis to prevent fatal outcome.
- 12 July 2018
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 12 (1) , 201
Open AccessLethal outcome of granulomatous acanthamoebic encephalitis in a man who was human immunodeficiency virus-positive: a case report
Acanthamoeba species can cause disseminating infections in immunocompromised individuals. Here, we report a case of granulomatous acanthamoebic encephalitis with a lethal outcome in a 54-year-old German man who was human immunodeficiency virus-positive. The diagnosis was based on symptoms of progressive neurological deficits, including sensorimotor paralysis of his right leg and deteriorating alertness. Due to the rapid course and rather late diagnosis of the infection, effective treatment could not be applied and he died 12 days after hospital admission. To the best of our knowledge, this is the second case of granulomatous acanthamoebic encephalitis reported within Germany. Our case highlights the importance of early diagnosis of granulomatous acanthamoebic encephalitis to prevent fatal outcome.
- Open Access
- 1 January 2018
- Published by Elsevier in Annals of Intensive Care
- Vol. 8 (1) , 113
Sustained low efficiency dialysis should not be interrupted for performing transpulmonary thermodilution measurements
- 1 January 2018
- Published by Elsevier in Annals of Intensive Care
- Vol. 8 (1) , 113
Open AccessSustained low efficiency dialysis should not be interrupted for performing transpulmonary thermodilution measurements
- 23 June 2016
- Published by Georg Thieme Verlag KG in Kardiologie up2date
- Vol. 12 (02) , 135-151
Nichtkoronare Notfallinterventionen
Minimal invasive catheter guided procedures are rapidly increasing. Most recently, new techniques for valve replacement (e. g. transcatheter aortic valve implantation, TAVI) and valve repair (e. g. Mitralclip and others) have been introduced. Other procedures are the closure of left atrial appendage, closure devices for shunts, procedures of the aorta and peripheral vessels. Emergent situations can occur in all interventions which require a safe and definite solution. On the other hand minimal invasive procedure can be used in an emergent situation which occurs primarily. These are balloon aortic valvuloplasty in cardiac decompensation, pericardial effluent and tamponade, acute aortic syndrome, acute lung embolism, peripheral vessel damage, percutaneous circulatory support devices, retrival of devices lost in the heart and circulatory system. We give here a survey on the available approaches for non-coronary emergencies.
- 23 June 2016
- Published by Georg Thieme Verlag KG in Kardiologie up2date
- Vol. 12 (02) , 135-151
Nichtkoronare Notfallinterventionen
Minimal invasive catheter guided procedures are rapidly increasing. Most recently, new techniques for valve replacement (e. g. transcatheter aortic valve implantation, TAVI) and valve repair (e. g. Mitralclip and others) have been introduced. Other procedures are the closure of left atrial appendage, closure devices for shunts, procedures of the aorta and peripheral vessels. Emergent situations can occur in all interventions which require a safe and definite solution. On the other hand minimal invasive procedure can be used in an emergent situation which occurs primarily. These are balloon aortic valvuloplasty in cardiac decompensation, pericardial effluent and tamponade, acute aortic syndrome, acute lung embolism, peripheral vessel damage, percutaneous circulatory support devices, retrival of devices lost in the heart and circulatory system. We give here a survey on the available approaches for non-coronary emergencies.
- Open Access
- 4 November 2014
- Published by Springer Nature in Malaria Journal
- Vol. 13 (1) , 1-5
Severe Plasmodium knowlesi infection with multi-organ failure imported to Germany from Thailand/Myanmar
During the last two decades human infections with Plasmodium knowlesi are increasingly diagnosed in South East Asia and have also been reported in travellers. A severe case of imported P. knowlesi infection in a 73-year old German is presented, who had been travelling through Myanmar and Thailand for three weeks. Microscopy showed a parasitaemia of 3% and different parasite stages including band-forms resembling Plasmodium malariae. Due to the clinical picture of severe malaria and the microscopical aspect (combination of parasites resembling P. malariae and Plasmodium falciparum), P. knowlesi was suspected. The patient was treated with intravenous quinine; he was put on mechanical ventilation and catecholamines due to cardiorespiratory failure. Parasitaemia was cleared rapidly but renal function deteriorated resulting in intermittent haemodialysis. The patient was hospitalized for six weeks but he recovered completely without any physical sequelae. Plasmodium knowlesi mono-infection was confirmed by molecular methods later on. Plasmodium knowlesi infection has to be taken into account in feverish travellers returning from Thailand/Myanmar. Moreover this species can cause life-threatening or even lethal complications. Accordingly severe P. knowlesi infection should be treated like severe P. falciparum infections.
- 4 November 2014
- Published by Springer Nature in Malaria Journal
- Vol. 13 (1) , 1-5
Open AccessSevere Plasmodium knowlesi infection with multi-organ failure imported to Germany from Thailand/Myanmar
During the last two decades human infections with Plasmodium knowlesi are increasingly diagnosed in South East Asia and have also been reported in travellers. A severe case of imported P. knowlesi infection in a 73-year old German is presented, who had been travelling through Myanmar and Thailand for three weeks. Microscopy showed a parasitaemia of 3% and different parasite stages including band-forms resembling Plasmodium malariae. Due to the clinical picture of severe malaria and the microscopical aspect (combination of parasites resembling P. malariae and Plasmodium falciparum), P. knowlesi was suspected. The patient was treated with intravenous quinine; he was put on mechanical ventilation and catecholamines due to cardiorespiratory failure. Parasitaemia was cleared rapidly but renal function deteriorated resulting in intermittent haemodialysis. The patient was hospitalized for six weeks but he recovered completely without any physical sequelae. Plasmodium knowlesi mono-infection was confirmed by molecular methods later on. Plasmodium knowlesi infection has to be taken into account in feverish travellers returning from Thailand/Myanmar. Moreover this species can cause life-threatening or even lethal complications. Accordingly severe P. knowlesi infection should be treated like severe P. falciparum infections.
- Open Access
- 1 September 2011
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 13 (9) , 1019-1027
Potential Value of Automated Daily Screening of Cardiac Resynchronization Therapy Defibrillator Diagnostics for Prediction of Major Cardiovascular Events: Results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy) Study
Aim: To investigate whether diagnostic data from implanted cardiac resynchronization therapy defibrillators (CRT-Ds) retrieved automatically at 24 h intervals via a Home Monitoring function can enable dynamic prediction of cardiovascular hospitalization and death. Methods and results: Three hundred and seventy-seven heart failure patients received CRT-Ds with Home Monitoring option. Data on all deaths and hospitalizations due to cardiovascular reasons and Home Monitoring data were collected prospectively during 1-year follow-up to develop a predictive algorithm with a predefined specificity of 99.5%. Seven parameters were included in the algorithm: mean heart rate over 24 h, heart rate at rest, patient activity, frequency of ventricular extrasystoles, atrial–atrial intervals (heart rate variability), right ventricular pacing impedance, and painless shock impedance. The algorithm was developed using a 25-day monitoring window ending 3 days before hospitalization or death. While the retrospective sensitivities of the individual parameters ranged from 23.6 to 50.0%, the combination of all parameters was 65.4% sensitive in detecting cardiovascular hospitalizations and deaths with 99.5% specificity (corresponding to 1.83 false-positive detections per patient-year of follow-up). The estimated relative risk of an event was 7.15-fold higher after a positive predictor finding than after a negative predictor finding. Conclusion: We developed an automated algorithm for dynamic prediction of cardiovascular events in patients treated with CRT-D devices capable of daily transmission of their diagnostic data via Home Monitoring. This tool may increase patients’ quality of life and reduce morbidity, mortality, and health economic burden, it now warrants prospective studies. ClinicalTrials.gov NCT00376116.
- 1 September 2011
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 13 (9) , 1019-1027
Open AccessPotential Value of Automated Daily Screening of Cardiac Resynchronization Therapy Defibrillator Diagnostics for Prediction of Major Cardiovascular Events: Results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy) Study
Aim: To investigate whether diagnostic data from implanted cardiac resynchronization therapy defibrillators (CRT-Ds) retrieved automatically at 24 h intervals via a Home Monitoring function can enable dynamic prediction of cardiovascular hospitalization and death. Methods and results: Three hundred and seventy-seven heart failure patients received CRT-Ds with Home Monitoring option. Data on all deaths and hospitalizations due to cardiovascular reasons and Home Monitoring data were collected prospectively during 1-year follow-up to develop a predictive algorithm with a predefined specificity of 99.5%. Seven parameters were included in the algorithm: mean heart rate over 24 h, heart rate at rest, patient activity, frequency of ventricular extrasystoles, atrial–atrial intervals (heart rate variability), right ventricular pacing impedance, and painless shock impedance. The algorithm was developed using a 25-day monitoring window ending 3 days before hospitalization or death. While the retrospective sensitivities of the individual parameters ranged from 23.6 to 50.0%, the combination of all parameters was 65.4% sensitive in detecting cardiovascular hospitalizations and deaths with 99.5% specificity (corresponding to 1.83 false-positive detections per patient-year of follow-up). The estimated relative risk of an event was 7.15-fold higher after a positive predictor finding than after a negative predictor finding. Conclusion: We developed an automated algorithm for dynamic prediction of cardiovascular events in patients treated with CRT-D devices capable of daily transmission of their diagnostic data via Home Monitoring. This tool may increase patients’ quality of life and reduce morbidity, mortality, and health economic burden, it now warrants prospective studies. ClinicalTrials.gov NCT00376116.
- 27 September 2009
- Published by Springer Nature in Herz
- Vol. 34 (6) , 468-476
Die perkutane Mitralklappenanuloplastie mittels des VIACOR™-Koronarsinussystems zur Behandlung der funktionellen Mitralklappeninsuffizienz bei Herzinsuffizienz
- 27 September 2009
- Published by Springer Nature in Herz
- Vol. 34 (6) , 468-476
Die perkutane Mitralklappenanuloplastie mittels des VIACOR™-Koronarsinussystems zur Behandlung der funktionellen Mitralklappeninsuffizienz bei Herzinsuffizienz
- 27 August 2009
- Published by Springer Nature in Herz
- Vol. 34 (5) , 357-366
Die kathetergestützte Implantation einer Aortenklappenprothese
Die kalzifizierte Aortenklappenstenose ist der häufigste erworbene Herzklappenfehler. Die Betroffenen sind ältere Menschen in der 8. und 9. Lebensdekade, die häufig zusätzlich Komorbiditäten wie linksventrikuläre Dysfunktion, eingeschränkte Nierenfunktion und pulmonale Hypertonie sowie weitere Begleiterkrankungen (Diabetes mellitus, Schlaganfall, chronisch- obstruktive Lungenerkrankung) aufweisen. Bei vielen dieser Patienten sind operative Morbidität und Letalität so hoch, dass der chirurgische Aortenklappenersatz nicht durchgeführt werden kann. Andererseits ist die Prognose der Aortenklappenstenose äußerst schlecht, sind die typischen Symptome wie Belastungsdyspnoe, Synkope und Angina pectoris erst einmal aufgetreten. Für diese Patientengruppe kommt derzeit die kathetergestützte Aortenklappenprothesenimplantation als eine alternative Behandlungsmethode in Betracht. Die Aortenklappenbioprothese besteht aus einem ballonexpandierbaren oder selbstexpandierenden Stent, in den eine Herzklappe aus Rinder- oder Schweineperikard fixiert ist. Die Implantation erfolgt über einen retrograden, transfemoralen Zugang, die ballonexpandierbare Klappenprothese kann auch transapikal eingebracht werden. Alternativ kann auch die Arteria subclavia als Zugangsweg gewählt werden. Immer häufiger wird die Intervention in Analgosedierung, d.h. am wachen Patienten durchgeführt, was nur über den femoralen Zugang möglich ist. Die weitere Verkleinerung der derzeitigen Klappenprothesen und neue Prothesentypen, die sich zurzeit im experimentellen Stadium oder bereits in der klinischen Prüfung befinden, tragen dieser Entwicklung Rechnung. The calcified aortic stenosis is the dominating valve disease. Patients affected are most common elderly people in the 8th or 9th decade of their life who often show associated comorbidities like reduced left ventricular function, impaired renal function, pulmonary hypertension, and further diseases (diabetes mellitus, stroke, chronic obstructive pulmonary disease). In many cases perioperative morbidity and mortality are too high for surgical valve replacement and patients are rejected. Nevertheless, prognosis of aortic stenosis is worse, if the typical symptoms like dyspnea on exertion, syncope, and angina occur. The transcatheter aortic valve implantation is an alternative treatment for this particular group of patients. The aortic valve bioprosthesis consists of a balloon-expandable stent or a self-expandable frame, in which a valve of bovine or porcine pericardium is incorporated. The implantation is performed by retrograde access via the femoral artery; the balloon-expandable prosthesis can also be implanted by transapical approach. Alternatively, the subclavian artery is chosen for access. More frequently, the implantation is performed in analgosedation with the patient awake that favors the transfemoral approach. A further reduction of the available prosthesis and new types of valves which are under current experimental tests and clinical evaluation contribute to this development.
- 27 August 2009
- Published by Springer Nature in Herz
- Vol. 34 (5) , 357-366
Die kathetergestützte Implantation einer Aortenklappenprothese
Die kalzifizierte Aortenklappenstenose ist der häufigste erworbene Herzklappenfehler. Die Betroffenen sind ältere Menschen in der 8. und 9. Lebensdekade, die häufig zusätzlich Komorbiditäten wie linksventrikuläre Dysfunktion, eingeschränkte Nierenfunktion und pulmonale Hypertonie sowie weitere Begleiterkrankungen (Diabetes mellitus, Schlaganfall, chronisch- obstruktive Lungenerkrankung) aufweisen. Bei vielen dieser Patienten sind operative Morbidität und Letalität so hoch, dass der chirurgische Aortenklappenersatz nicht durchgeführt werden kann. Andererseits ist die Prognose der Aortenklappenstenose äußerst schlecht, sind die typischen Symptome wie Belastungsdyspnoe, Synkope und Angina pectoris erst einmal aufgetreten. Für diese Patientengruppe kommt derzeit die kathetergestützte Aortenklappenprothesenimplantation als eine alternative Behandlungsmethode in Betracht. Die Aortenklappenbioprothese besteht aus einem ballonexpandierbaren oder selbstexpandierenden Stent, in den eine Herzklappe aus Rinder- oder Schweineperikard fixiert ist. Die Implantation erfolgt über einen retrograden, transfemoralen Zugang, die ballonexpandierbare Klappenprothese kann auch transapikal eingebracht werden. Alternativ kann auch die Arteria subclavia als Zugangsweg gewählt werden. Immer häufiger wird die Intervention in Analgosedierung, d.h. am wachen Patienten durchgeführt, was nur über den femoralen Zugang möglich ist. Die weitere Verkleinerung der derzeitigen Klappenprothesen und neue Prothesentypen, die sich zurzeit im experimentellen Stadium oder bereits in der klinischen Prüfung befinden, tragen dieser Entwicklung Rechnung. The calcified aortic stenosis is the dominating valve disease. Patients affected are most common elderly people in the 8th or 9th decade of their life who often show associated comorbidities like reduced left ventricular function, impaired renal function, pulmonary hypertension, and further diseases (diabetes mellitus, stroke, chronic obstructive pulmonary disease). In many cases perioperative morbidity and mortality are too high for surgical valve replacement and patients are rejected. Nevertheless, prognosis of aortic stenosis is worse, if the typical symptoms like dyspnea on exertion, syncope, and angina occur. The transcatheter aortic valve implantation is an alternative treatment for this particular group of patients. The aortic valve bioprosthesis consists of a balloon-expandable stent or a self-expandable frame, in which a valve of bovine or porcine pericardium is incorporated. The implantation is performed by retrograde access via the femoral artery; the balloon-expandable prosthesis can also be implanted by transapical approach. Alternatively, the subclavian artery is chosen for access. More frequently, the implantation is performed in analgosedation with the patient awake that favors the transfemoral approach. A further reduction of the available prosthesis and new types of valves which are under current experimental tests and clinical evaluation contribute to this development.
- 1 August 2009
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 2 (4) , 277-284
Percutaneous Transvenous Mitral Annuloplasty
We assessed the safety and feasibility of permanent implantation of a novel coronary sinus mitral repair device (PTMA, Viacor Inc). Symptomatic (New York Heart Association class 2 or 3) patients with primarily functional mitral regurgitation (MR) were included. A diagnostic PTMA procedure was performed in the coronary sinus venous continuity. MR was assessed and the PTMA device adjusted to optimize efficacy. If MR reduction (> or =1 grade) was observed, placement of a PTMA implant was attempted. Implanted patients were evaluated with echocardiographic, quality of life, and exercise capacity metrics. Nineteen patients received a diagnostic PTMA study. Diagnostic PTMA was effective in 13 patients (MR grade 3.2+/-0.6 reduced to 2.0+/-1.0), and PTMA implants were placed in 9 patients. Four devices were removed uneventfully (7, 84, 197, and 216 days), 3 for annuloplasty surgery due to observed PTMA device migration and/or diminished efficacy. No procedure or device-related major adverse events with permanent sequela were observed in any of the diagnostic or implant patients. Sustained reductions of mitral annulus septal-lateral dimension from 3D echo reconstruction dimensions were observed (4.0+/-1.2 mm at 3 months). Percutaneous implantation of the PTMA device is feasible and safe. Acute results demonstrate a possibly meaningful reduction of MR in responding patients. Sustained favorable geometric modification of the mitral annulus has been observed, though reduction of MR has been limited. The PTMA method warrants continued evaluation and development.
- 1 August 2009
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 2 (4) , 277-284
Percutaneous Transvenous Mitral Annuloplasty
We assessed the safety and feasibility of permanent implantation of a novel coronary sinus mitral repair device (PTMA, Viacor Inc). Symptomatic (New York Heart Association class 2 or 3) patients with primarily functional mitral regurgitation (MR) were included. A diagnostic PTMA procedure was performed in the coronary sinus venous continuity. MR was assessed and the PTMA device adjusted to optimize efficacy. If MR reduction (> or =1 grade) was observed, placement of a PTMA implant was attempted. Implanted patients were evaluated with echocardiographic, quality of life, and exercise capacity metrics. Nineteen patients received a diagnostic PTMA study. Diagnostic PTMA was effective in 13 patients (MR grade 3.2+/-0.6 reduced to 2.0+/-1.0), and PTMA implants were placed in 9 patients. Four devices were removed uneventfully (7, 84, 197, and 216 days), 3 for annuloplasty surgery due to observed PTMA device migration and/or diminished efficacy. No procedure or device-related major adverse events with permanent sequela were observed in any of the diagnostic or implant patients. Sustained reductions of mitral annulus septal-lateral dimension from 3D echo reconstruction dimensions were observed (4.0+/-1.2 mm at 3 months). Percutaneous implantation of the PTMA device is feasible and safe. Acute results demonstrate a possibly meaningful reduction of MR in responding patients. Sustained favorable geometric modification of the mitral annulus has been observed, though reduction of MR has been limited. The PTMA method warrants continued evaluation and development.
- 16 May 2009
- Published by Springer Nature in Herz
- Vol. 34 (3) , 206-210
Dekompensiertes Klappenvitium: das Revival der Ballonvalvuloplastie – perkutane Klappeninterventionen
- 16 May 2009
- Published by Springer Nature in Herz
- Vol. 34 (3) , 206-210
Dekompensiertes Klappenvitium: das Revival der Ballonvalvuloplastie – perkutane Klappeninterventionen
- 1 January 2009
- Published by Taylor & Francis in Minimally Invasive Therapy & Allied Technologies
- Vol. 18 (3) , 156-163
Percutaenous mitral valve: A non-stented coronary sinus device for the treatment of functional mitral regurgitation in heart failure patients
Functional mitral regurgitation in heart failure limits survival in a severity-graded fashion. Even mild mitral regurgitation doubles mortality risk. We report the use of a non-stented coronary sinus device to reduce mitral annulus dimension in order to re-establish mitral valve competence. The device (PTMA™, Viacor, Inc., Wilmington, MA, USA) consists of a multi-lumen PTFE (Teflon) PTMA catheter in which Nitinol (nickel-titanium alloy) treatment rods are advanced. For individual use up to three rods of different length and stiffness can be used. Therefore dimension reduction can be performed in an incremental fashion. Fluoroscopy and 3 D echocardiography are performed throughout the procedure to visiualize the positioning and confirm maximum treatment effect. The case describes the use and the effect of PTMA treatment. Safety and efficacy of the PTMA device will be investigated in the upcoming PTOLEMY 2 trial.
- 1 January 2009
- Published by Taylor & Francis in Minimally Invasive Therapy & Allied Technologies
- Vol. 18 (3) , 156-163
Percutaenous mitral valve: A non-stented coronary sinus device for the treatment of functional mitral regurgitation in heart failure patients
Functional mitral regurgitation in heart failure limits survival in a severity-graded fashion. Even mild mitral regurgitation doubles mortality risk. We report the use of a non-stented coronary sinus device to reduce mitral annulus dimension in order to re-establish mitral valve competence. The device (PTMA™, Viacor, Inc., Wilmington, MA, USA) consists of a multi-lumen PTFE (Teflon) PTMA catheter in which Nitinol (nickel-titanium alloy) treatment rods are advanced. For individual use up to three rods of different length and stiffness can be used. Therefore dimension reduction can be performed in an incremental fashion. Fluoroscopy and 3 D echocardiography are performed throughout the procedure to visiualize the positioning and confirm maximum treatment effect. The case describes the use and the effect of PTMA treatment. Safety and efficacy of the PTMA device will be investigated in the upcoming PTOLEMY 2 trial.